NCT06673641View on ClinicalTrials.gov

A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.

PHASE1CompletedINTERVENTIONAL
Enrollment

382

Participants

Timeline

Start Date

May 13, 2024

Primary Completion Date

September 3, 2024

Study Completion Date

September 3, 2024

Conditions
Acne Vulgaris
Interventions
DRUG

Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%

The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.

DRUG

CABTREO Topical Gel

The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.

DRUG

Placebo Control

The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.

Trial Locations (1)

10532

Taro Pharmaceuticals USA Inc., Hawthorne

All Listed Sponsors
lead

Sun Pharmaceutical Industries, Inc.

INDUSTRY

NCT06673641 - A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris. | Biotech Hunter | Biotech Hunter